IGF1 and neoplasm: Lastly, experimental cancer therapeutics are exploring synthetic molecules mimicking IGFBP’s IGF-1 binding properties, though their effectiveness is limited by IGF-1 independent and sometimes tumor-promoting actions of IGFBPs [147,148].